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Hot flushes (vasomotor symptoms) are experienced by approximately 73% of postmenopausal women, and the associated sleep disturbances, fatigue, and decreased cognitive function lead to a reduction in their quality of life and an increased use of medical resources. 2 A hypothalamic mechanism is well established in the understanding of hot flushes, 3 but the pathways involved have been unclear, thus reducing therapeutic options. Novel hypothalamic neuropeptide-signalling pathways have shed light on the central regulation of both reproductive and thermoregulatory systems and the links between them, 4 and might now lead to specific therapies. The menopause results in oestrogen deficiency, with loss of feedback regulation of hypothalamic gonadotropinreleasing hormone (GnRH). The kisspeptin-neurokinin B (NKB)-dynorphin (KNDy) signalling system in the hypothalamus is the proximate and obligate stimulus of GnRH secretion, and is hypertrophied after the menopause. 4, 5 Hypothalamic NKB neurons also project to the medial preoptic area, the hypothalamic site of thermoregulatory neuronal pathways, and evidence exists that these NKB neurons are a key link between the endocrine changes of the menopause and vasomotor symptoms. 4 Flushing, like thermoregulation, is controlled centrally but effected peripherally, and blood flow to the skin is also increased in postmenopausal women with severe flushing. 6 NKB neurons might also facilitate cutaneous vasodilatation and contribute to oestrogenic modulation of body temperature. ). This finding was also supported by an objective assessment of flushes, using the Bahr sternal skin conductance monitor. Reductions in the number of flushes might be less important to women than measures of quality of life, thus it is of interest that the authors found hot flush severity, bother, and interference to be significantly reduced during treatment with MLE4901. However, in Prague and colleagues' study, no improvements occurred in the sexual symptoms commonly reported after menopause (MENQOL sexual domain score adjusted means: placebo 2·15 [95% CI 1·84-2·51] vs MLE4901 1·98 [1·68-2·30]; p=0·24). As an index of GnRH secretion, luteinising hormone pulse frequency was unchanged in the treatment group, although other measures of pulsatile secretion altered with increases in amplitude and orderliness of luteinising hormone pulse. Thus, although NKB pathways regulate both the vasomotor and reproductive systems, separate effects can be identified, and these might vary with the endocrine environment. Most withdrawals from the study were for reasons unrelated to treatment, and no serious adverse events occurred with MLE4901, although three women developed liver enzyme elevations (alanine aminotransferase was 4·5-5·9 times the upper limit of normal), which normalised within 90 days. The limitations of the trial include its small size (of 68 women screened, only 28 completed the trial and were included in the per-protocol analysis) and short duration of treatment.
The current gold-standard treatment for menopausal hot flushes is oestrogen, but in some women its maximum efficacy might take many weeks to achieve.
9
Selective serotonin-reuptake inhibitors are a nonhormonal alternative with similar improvements in flush reduction, 10 but might not be well tolerated. And, although oestrogen is an effective treatment for flushing, oestrogen-free therapies are necessary for women with breast cancer. The severity of hot flushes in these women might be a major contributor to reduced adherence to the recommended 10 years of endocrine therapy, increasing recurrence and mortality. 11 Additionally, hot flushes are not the sole preserve of women: 44-80% of men treated for advanced prostate cancer have hot flushes, and 25% describe them as the most significant adverse effect on their quality of life. 12 Although the role of oestrogen in the maintenance of bone and cardiovascular health is crucial to postreproductive health and quality of life during older age, vasomotor symptoms are the most commonly reported, and often the most acutely distressing, symptom of menopause. Therefore, NKB antagonists are an exciting development in an area in which the last development in mechanistic understanding is more than 20 years old. Larger trials of clinically relevant duration examining benefits relative to established treatments are needed and might lead to a much needed addition to a very small toolbox of treatments for hot flushes.
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